Open AccessTwo randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania
Author(s) -
Eduard Vieta,
Gary S. Sachs,
Denise Chang,
Johan Hellsten,
Claudette Brewer,
Timothy Peters-Strickland,
Nanco Hefting
Publication year - 2021
Publication title -
journal of psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.333
H-Index - 114
eISSN - 1461-7285
pISSN - 0269-8811
DOI - 10.1177/0269881120985102
Subject(s) - young mania rating scale , akathisia , mania , placebo , medicine , bipolar i disorder , tolerability , bipolar disorder , randomized controlled trial , psychology , partial agonist , adverse effect , anesthesia , psychiatry , schizophrenia (object oriented programming) , antipsychotic , antagonist , lithium (medication) , alternative medicine , receptor , pathology
Brexpiprazole is a dopamine/serotonin receptor partial agonist (D 2 , 5-HT 1A ) and antagonist (5-HT 2A ) approved for treatment of schizophrenia and major depressive disorder (adjunct to antidepressants).